Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.64 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22765925 | 1.00 | FAAH (0.64) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL6361669 | 1.00 | FAAH (0.64) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL8986128 | 1.00 | FAAH (0.64) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL10689512 | 0.92 | FAAH (0.60) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL9319903 | 0.92 | FAAH (0.60) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL24339916 | 0.91 | FAAH (0.58) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL11644276 | 0.91 | FAAH (0.69) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL5410583 | 0.91 | FAAH (0.58) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL1004187 | 0.91 | FAAH (0.58) | FAAHASAH1HSP90AA1MEN1MAPK1 | |
| SCHEMBL9061545 | 0.91 | FAAH (0.58) | FAAHASAH1HSP90AA1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704888-A2 | COMPOSITIONS CONTAINING POLYNUCLEOTIDE AND POLYPEPTIDE AMPHIPHILES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226775-A2 | COMPOSITIONS CONTAINING POLYNUCLEOTIDE AND POLYPEPTIDE AMPHIPHILES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11235032-B2 | Combination immunotherapy dosing regimen for immune checkpoint blockade | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210338833-A1 | CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-11-04 | — | — | US | disclosed |
| US-20210340524-A1 | METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-04 | — | — | US | disclosed |
| US-20210187112-A1 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-06-24 | — | — | US | disclosed |
| US-20200230208-A1 | COMBINATION IMMUNOTHERAPY DOSING REGIMEN FOR IMMUNE CHECKPOINT BLOCKADE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-07-23 | — | — | US | disclosed |
| US-20200230221-A1 | COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2020-07-23 | — | — | US | disclosed |
| WO-2019060425-A1 | COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-28 | — | — | WO | disclosed |
| US-10029016-B2 | Immunostimulatory compositions and methods of use thereof | MASSACHUSETTS INSITUTE OF TECHNOLOGY (US) | 2018-07-24 | — | — | US | disclosed |
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074239-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| EP-0957929-A4 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114404-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6426335-B1 | ADMINISTERING COMPLEX OF NUCLEIC ACID LIGAND | GILEAD SCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-6168778-B1 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes | NEXSTAR PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | disclosed |
| US-6051698-A | ARTIFICIAL LIGAND INCLUDES 2'FLUORO MODIFIED NUCLEOTIDES; FOR ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS AGAINST KARPOSI'S SARCOMA, TREATMENT OF MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2000-04-18 | — | — | US | disclosed |
| EP-0957929-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998018480-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338833-A1 | CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF | CD47, HAVCR2, CD74 | FAAH 4168/4885ASAH1 1033/4885HSP90AA1 1861/4885 |
| US-11235032-B2 | Combination immunotherapy dosing regimen for immune checkpoint blockade | IL2, IL2RA, PDCD1LG2 | FAAH 4726/4885ASAH1 4038/4885HSP90AA1 804/4885 |
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | FAAH 2642/4885ASAH1 1326/4885HSP90AA1 458/4885 |
| US-10029016-B2 | Immunostimulatory compositions and methods of use thereof | PHOSPHO1, MYD88, CD47 | FAAH 2350/4885ASAH1 1368/4885HSP90AA1 1964/4885 |
| US-20200230208-A1 | COMBINATION IMMUNOTHERAPY DOSING REGIMEN FOR IMMUNE CHECKPOINT BLOCKADE | IL2, IL2RA, PDCD1LG2 | FAAH 4726/4885ASAH1 4038/4885HSP90AA1 804/4885 |
| US-20200230221-A1 | COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF | CD2, CD4, CD74 | FAAH 1671/4885ASAH1 602/4885HSP90AA1 2815/4885 |
| US-20210187112-A1 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | PHOSPHO1, MYD88, CD47 | FAAH 2350/4885ASAH1 1368/4885HSP90AA1 1964/4885 |
| US-20210340524-A1 | METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF | HAVCR2, CD47, CD74 | FAAH 4146/4885ASAH1 814/4885HSP90AA1 1867/4885 |
| US-20030114404-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | FAAH 2642/4885ASAH1 1326/4885HSP90AA1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.